Sickle Cell Disease study: Nicotinamide
Official title A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
ClinicalTrials.gov ID: NCT04055818
What this study is testing
What is Nicotinamide?
An investigational oral vitamin B3 being studied as a potential treatment for sickle cell disease. It is designed to raise cellular NAD+ levels, which may influence red blood cell metabolism.
Also referred to as Vitamin B3.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see how safe and how the body handles these medicines, alone or combined, in sickle cell disease.
- Who it's for
- People who have high‑risk sickle cell disease.
- What's involved
- Participants will be randomly assigned to take either THU‑decitabine, nicotinamide, or the two together, and will have study visits for monitoring and tests.
- Phase 1: an early, usually small safety study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age 18 years or older.
- Written informed consent provided by the subject before study entry.
- Confirmed sickle cell disease (SCD) as determined by hemoglobin electrophoresis or liquid chromatography.
- Subject is in his/her steady state and not having any acute complication due to SCD (i.e., hospitalization, acute pain, or acute chest syndrome in...
- Weight at least 40kg
You likely can't join if
- Inability to give informed consent.
- Experienced severe sepsis or septic shock within the previous 12 weeks.
- Last HU dose was ingested within the previous 4 weeks.
- Currently pregnant or breast-feeding.
- Alanine Aminotransferase (ALT) ≥ 3 times the upper limit of normal or albumin \<2.0 mg/dL or direct (conjugated) bilirubin ≥ 1.5 mg/dl.
- Serum creatinine \>2.9 mg/dL and calculated creatinine clearance \<30 mL/min.
See the full eligibility criteria
- Age 18 years or older.
- Written informed consent provided by the subject before study entry.
- Confirmed sickle cell disease (SCD) as determined by hemoglobin electrophoresis or liquid chromatography.
- Subject is in his/her steady state and not having any acute complication due to SCD (i.e., hospitalization, acute pain, or acute chest syndrome in the past 14 days).
- Weight at least 40kg
- Regular compliance with comprehensive care and previous therapy.
- Symptomatic SCD is defined as having one of following, despite at least 6 months of hydroxyurea therapy, or refuse to take hydroxyurea for personal reasons: fetal hemoglobin \<0.5 g/dL, or 3 or more pain episodes per...
- Inability to give informed consent.
- Experienced severe sepsis or septic shock within the previous 12 weeks.
- Last HU dose was ingested within the previous 4 weeks.
- Currently pregnant or breast-feeding.
- Alanine Aminotransferase (ALT) ≥ 3 times the upper limit of normal or albumin \<2.0 mg/dL or direct (conjugated) bilirubin ≥ 1.5 mg/dl.
- Serum creatinine \>2.9 mg/dL and calculated creatinine clearance \<30 mL/min.
- Platelet count \>800 x 109/L.
- Absolute neutrophil count \<1.5 x 109/L.
- Female of active childbearing potential who is unwilling to use at least one of the two following forms of birth control: (i) not having heterosexual sexual contact beginning at the screening visit and continuing until...
- Sexually active male who is unwilling to use a condom when engaging in any sexual contact with a female with child-bearing potential, beginning at the screening visit and continuing until 4 weeks after taking the last...
- Altered mental status or recurrent seizures requiring anti-seizure medications.
- Moribund or any concurrent disease (e.g., hepatic, renal, cardiac, metabolic) of such severity that death within 24 weeks is likely.
- Concurrent diagnosis of malignancy including known Myelodysplastic syndrome, leukemia, or an abnormal karyotype.
- New York Heart Association (NYHA) class III/IV status.
- Eastern Co-operative Oncology Group (ECOG) performance status ≥3.
- Participant is on chronic transfusion therapy
- Known history of illicit drug or alcohol abuse within the past 12 months.
- Other experimental or investigational drug therapy in the past 28 days.
- Taking l-glutamine within the last 28 days
- Being positive for HIV infection
The study team makes the final eligibility decision.
Where it is enrolling
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Chicago, Illinois, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.